Related Experiment Video

Updated: May 19, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review)

Giulia Costanza Leonardi1, Saverio Candido, Maurizio Carbone

  • 1Department of Biomedical Sciences, Laboratory of Translational Oncology and Functional Genomics, University of Catania, Catania, Italy.

Molecular Medicine Reports
|August 4, 2012
PubMed

Insights

Papillary thyroid carcinoma, the most common thyroid cancer, often relapses post-treatment. This review highlights the BRAF V600E mutation

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Papillary thyroid carcinoma (PTC) is the most prevalent thyroid malignancy.
  • Despite curability, PTC recurrence rates necessitate understanding its pathogenesis.
  • The MAPK pathway is recognized for its role in PTC development.

Purpose of the Study:

  • To review the significance of the BRAF V600E mutation in thyroid cancer.
  • To explore the mutation's role in PTC development and progression.
  • To discuss the clinical implications of BRAF V600E detection for novel therapies.

Main Methods:

  • Literature review focusing on BRAF V600E mutation in thyroid cancer.
  • Analysis of studies implicating the MAPK pathway in PTC pathogenesis.
  • Synthesis of clinical data related to BRAF V600E in thyroid cancer.

Main Results:

  • The BRAF V600E mutation is a key factor in PTC development and progression.
  • This mutation is linked to the MAPK signaling pathway.
  • BRAF V600E detection offers insights into clinical management and therapeutic strategies.

Conclusions:

  • BRAF V600E mutation is critical in papillary thyroid carcinoma pathogenesis.
  • Identifying this mutation is essential for developing targeted therapies.
  • Detection of BRAF V600E mutation opens new avenues for thyroid cancer treatment.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...